FDA accepts NDA for combination drug to treat type 2 diabetes
If FDA approves the combination tablet, it will bring together the distinct mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor.